Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of 19,132 shares of common stock on May 14, 2026. The shares were valued at $3.92 per share for reporting purposes, bringing her direct holdings to 19,132 shares. This is a compensation-related award, not an open-market purchase.
Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock. On May 14, 2026, he acquired 51,020 shares at an indicated value of $3.92 per share as a grant or award, rather than an open-market purchase. Following this award, his direct holdings in Whitehawk Therapeutics increased to 448,126 Common Stock shares, reflecting a routine compensation-related equity grant instead of a discretionary market trade.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported a compensation-related stock award on a Form 4. He acquired 38,265 shares of common stock on May 14, 2026 in a transaction classified as a grant or award at a reference price of $3.92 per share. Following this award, his directly held ownership increased to 333,489 shares of Whitehawk Therapeutics common stock. This filing reflects an equity grant rather than an open-market purchase or sale.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported an equity compensation grant of Common Stock. He acquired 51,021 shares at an indicated value of $3.92 per share as a grant, bringing his direct holdings to 569,643 shares after the transaction.
Whitehawk Therapeutics director Caley Castelein reported new share and warrant awards. He received a grant of 255,102 shares of Common Stock at $3.92 per share, bringing his directly held Common Stock to 274,796 shares.
Entities associated with him, specifically KVP Capital, LP, now hold 2,165,998 shares of Common Stock indirectly and a Pre-Funded Warrant to acquire 2,072,756 additional Common shares at an exercise price of $0.0001 per share. The warrant can be exercised on or after May 14, 2026, but includes a 4.99% beneficial ownership cap. Castelein is Managing Director of KVP Capital and disclaims beneficial ownership in those indirect holdings except for his pecuniary interest.
Whitehawk Therapeutics’ major holder Avoro has updated its ownership disclosure following a new PIPE financing involving pre-funded warrants. Avoro Life Sciences, through Avoro Capital, agreed to buy 6,377,714 pre-funded warrants at a purchase price of $3.9199 per underlying share, with an exercise price of $0.0001 per share.
Avoro Capital Advisors LLC reports beneficial ownership of 15,893,516 shares of Common Stock, or 19.99% of the class, including 13,044,114 shares issuable upon exercise of pre-funded warrants, subject to a 19.99% beneficial ownership blocker. Avoro Ventures LLC reports 2,288,950 shares, or 4.1%, including 1,666,600 pre-funded warrant shares. Behzad Aghazadeh reports 18,292,675 shares, or 19.99%, including director options and 14,710,714 pre-funded warrant shares, all calculated against 68,494,043 shares of Common Stock.
Whitehawk Therapeutics, Inc. reported that accounts managed by Avoro Capital Advisors LLC acquired 6,377,714 pre-funded warrants to buy common stock in a private placement. The warrants have a token exercise price of $0.0001 per share and were priced at $3.9199 per warrant.
The warrants become exercisable on or after May 12, 2026, but a 19.99% ownership blocker limits exercises so the reporting persons do not exceed 19.99% of Whitehawk’s outstanding common stock. Following this transaction, the reporting persons report beneficial ownership of 14,710,714 pre-funded warrants, while expressly disclaiming beneficial ownership beyond their pecuniary interest.
Whitehawk Therapeutics entered into a private investment in public equity financing expected to raise gross proceeds of approximately $87.5 million. The company is selling 4,330,866 shares of common stock at $3.92 per share and 17,991,021 pre-funded warrants at $3.9199 each, with an exercise price of $0.0001 per share. Closing is expected on May 14, 2026, subject to customary conditions, and certain executives, directors and affiliated funds committed $39.75 million. Net proceeds, together with existing cash, are intended for working capital and advancing Whitehawk’s antibody drug conjugate pipeline, and are expected to extend the company’s cash runway into the second half of 2028. Executives and directors agreed to 60‑day lock-ups, and the company plans to file a resale registration statement for the new securities.
Whitehawk Therapeutics reported first-quarter 2026 results with a net loss of $22.2 million, reflecting its transition to a pure clinical-stage antibody drug conjugate (ADC) company after selling its FYARRO business in 2025.
The company generated no revenue in the quarter versus $7.1 million a year earlier, when results included FYARRO sales and an $87.4 million gain on that divestiture. Operating expenses were $23.5 million, driven mainly by $17.2 million in research and development for its three ADC programs. Cash, cash equivalents and short-term investments totaled $123.0 million at March 31, 2026, and management believes existing resources can fund planned operations into 2028.
Whitehawk Therapeutics reported first quarter 2026 results, highlighting its transition to a pure R&D oncology company. Cash, cash equivalents and short-term investments were $123.0 million as of March 31, 2026, which the company anticipates will fund operations into 2028.
Whitehawk posted a net loss of $22.2 million for the quarter, compared with net income of $73.0 million a year earlier, when results included an $87.4 million gain on the sale of Aadi Subsidiary and $7.1 million of product sales. Research and development expenses rose to $17.2 million, driven in part by $5.3 million of development milestones under a WuXi Biologics license agreement.
Operationally, the company is enrolling Phase 1 trials for HWK‑007 and HWK‑016, plans to submit an IND for HWK‑206 in mid‑2026 with Phase 1 recruitment targeted for Q3 2026, and expects initial Phase 1 data for HWK‑007 and HWK‑016 in the first half of 2027.